End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
88.9 TWD | -1.11% |
|
-2.31% | +8.41% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- With an expected P/E ratio at 92.89 and 23.39 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.41% | 758M | C- | ||
+15.19% | 122B | B+ | ||
+19.91% | 113B | B+ | ||
+8.24% | 22.84B | B | ||
-19.80% | 20.72B | B+ | ||
-16.19% | 16.51B | A- | ||
-13.45% | 16.39B | B | ||
-44.35% | 15.83B | A- | ||
+2.13% | 13.49B | C+ | ||
+66.67% | 11.67B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4147 Stock
- Ratings TaiMed Biologics Inc.